{"id":"https://openalex.org/W3020002201","doi":"https://doi.org/10.1093/jnci/djaa055","title":"Trastuzumab: Weighing the Benefits and the Risks","display_name":"Trastuzumab: Weighing the Benefits and the Risks","publication_year":2020,"publication_date":"2020-04-27","ids":{"openalex":"https://openalex.org/W3020002201","doi":"https://doi.org/10.1093/jnci/djaa055","mag":"3020002201","pmid":"https://pubmed.ncbi.nlm.nih.gov/32343773"},"language":"en","primary_location":{"id":"doi:10.1093/jnci/djaa055","doi":"https://doi.org/10.1093/jnci/djaa055","is_oa":false,"landing_page_url":"https://doi.org/10.1093/jnci/djaa055","pdf_url":null,"source":{"id":"https://openalex.org/S98010888","display_name":"JNCI Journal of the National Cancer Institute","issn_l":"0027-8874","issn":["0027-8874","1460-2105"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI: Journal of the National Cancer Institute","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7824039","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040813731","display_name":"Anne Hudson Blaes","orcid":"https://orcid.org/0000-0002-5433-4810","observed_orcids":["https://orcid.org/0000-0002-5433-4810"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Anne H Blaes","raw_affiliation_strings":["Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN 55455, USA"],"raw_orcid":"https://orcid.org/0000-0002-5433-4810","affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN 55455, USA","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068207600","display_name":"Chau T. Dang","orcid":"https://orcid.org/0000-0001-5133-2265","observed_orcids":["https://orcid.org/0000-0001-5133-2265"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chau Dang","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5040813731"],"corresponding_institution_ids":["https://openalex.org/I130238516"],"apc_list":{"value":5436,"currency":"USD","value_usd":5436},"apc_paid":null,"fwci":0.2405,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.51906158,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"112","issue":"12","first_page":"1181","last_page":"1182"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8370000123977661},{"id":"https://openalex.org/keywords/premature-treatment-discontinuation","display_name":"premature treatment discontinuation","score":0.8019999861717224},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.718999981880188},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.7760000228881836},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.996999979019165},{"id":"https://openalex.org/keywords/adverse-cardiac-events","display_name":"adverse cardiac events","score":0.7039999961853027},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.6060000061988831},{"id":"https://openalex.org/keywords/hera-trial","display_name":"HERA trial","score":0.5809999704360962},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.4309999942779541},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.31700000166893005}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7936854362487793},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4957057237625122},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33820414543151855},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33710765838623047},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.31542864441871643},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2160685658454895}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009864","descriptor_name":"Ontario","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1093/jnci/djaa055","doi":"https://doi.org/10.1093/jnci/djaa055","is_oa":false,"landing_page_url":"https://doi.org/10.1093/jnci/djaa055","pdf_url":null,"source":{"id":"https://openalex.org/S98010888","display_name":"JNCI Journal of the National Cancer Institute","issn_l":"0027-8874","issn":["0027-8874","1460-2105"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI: Journal of the National Cancer Institute","raw_type":"journal-article"},{"id":"pmid:32343773","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32343773","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Cancer Institute","raw_type":"Editorial"},{"id":"pmh:oai:pubmedcentral.nih.gov:7824039","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7824039","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"J Natl Cancer Inst","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:7824039","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7824039","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"J Natl Cancer Inst","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Zero hunger","score":0.5199999809265137,"id":"https://metadata.un.org/sdg/2"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1996778928","https://openalex.org/W2095633632","https://openalex.org/W2095861620","https://openalex.org/W2162982444","https://openalex.org/W2171277704","https://openalex.org/W2379981061","https://openalex.org/W2588881638","https://openalex.org/W2609928112","https://openalex.org/W2624590002","https://openalex.org/W2805213545","https://openalex.org/W2806629158","https://openalex.org/W2889673459","https://openalex.org/W2902218997","https://openalex.org/W2948720210","https://openalex.org/W2948726637","https://openalex.org/W3006134372","https://openalex.org/W3020654673"],"related_works":["https://openalex.org/W2342209702","https://openalex.org/W2945034398","https://openalex.org/W2001196910","https://openalex.org/W3024330839","https://openalex.org/W2468646525","https://openalex.org/W4383618614","https://openalex.org/W2095633632","https://openalex.org/W2221528691","https://openalex.org/W2409773829","https://openalex.org/W2107622303"],"abstract_inverted_index":{"Within":[0],"this":[1,151,201],"issue":[2],"of":[3,13,16,54,80,88,116,119,138,141,170,200,206,228,261,270,277,283,297,315,326,338,351,360,363,412,417,436,472,483,499,506,551,584,669,678,741,836,852,908,952,957,983,996,1012,1029,1049,1054],"the":[4,11,32,52,117,168,173,197,213,225,229,237,275,280,302,342,348,392,410,437,497,527,533,539,548,563,570,581,663,676,704,723,739,745,748,770,783,791,826,955,1000,1068,1084],"Journal,":[5],"Rushton":[6],"and":[7,82,183,236,241,304,310,432,454,490,536,618,643,693,707,715,750,972,1044],"colleagues":[8],"(1)":[9],"report":[10],"outcomes":[12,21,62,344,839,889],"premature":[14,120,136,834,850],"discontinuation":[15,67,69,121,137,835,851],"trastuzumab":[17,56,89,139,155,171,207,218,271,298,339,418,484,507,585,598,616,641,671,689,718,763,765,776,796,801,823,837,845,853,920,953,997,1030,1055],"on":[18,60,265,369,594,744,967],"breast":[19,28,47,178,425,487,555,620,645,684,698,877,931],"cancer":[20,29,48,61,165,179,488,556,621,646,685,699],"in":[22,39,133,163,172,192,224,292,300,320,391,419,434,452,485,508,532,538,562,569,580,703,769,825,840,865,875,999,1024,1062],"5547":[23],"women":[24,43,108,353,681],"with":[25,31,65,135,217,252,294,323,422,503,510,567,682,696,708,728,805,940],"early-stage":[26,423,553],"HER2-positive":[27,46,177,424,554,683,697,758,909,930],"treated":[30,44,322,702],"adjuvant":[33,214,475,615,640,670,775,795,827,1001],"trastuzumab.":[34,327,636,661,1013],"Using":[35],"administrative":[36],"claims":[37],"data":[38],"Ontario,":[40],"Canada,":[41],"for":[42,45,70,106,156,176,515,518,604,609,680,726,747,757,778,803,928,1036,1041,1082],"2007-2016,":[49],"they":[50,867],"assessed":[51,409],"impact":[53,411],"full":[55,113],"treatment":[57,114,439],"(17-18":[58,272],"cycles)":[59,273],"as":[63,675,768,781],"compared":[64,502,566],"early":[66],"([1]":[68],"cardiac":[71,316,455,610,1019,1042],"events":[72,577],"[CEs],":[73],"[2]":[74],"no":[75,84,290,450],"CEs":[76,390],"but":[77,90],"<16":[78,86],"cycles":[79,87,161,780],"trastuzumab,":[81,361],"[3]":[83],"CEs,":[85],">30":[91],"days":[92],"since":[93],"last":[94],"trastuzumab)":[95],"(2).":[96],"The":[97,313,403,427],"5-year":[98,528],"disease-free":[99,628,653],"survival":[100,128],"(DFS)":[101],"was":[102,130,208,219,289,318,430,449,530,560],"statistically":[103],"significantly":[104],"lower":[105,319],"those":[107,134,321,605,804,855,1037],"who":[109,842,856,917,978],"did":[110],"not":[111,373,522,542,887,894,1007],"receive":[112,762],"regardless":[115,140],"cause":[118,142],"(94.1%":[122],"vs":[123,144,357,365,397,414,480,587],"80%,":[124],"81.4%,":[125],"82.4%).":[126],"Overall":[127],"(OS)":[129],"also":[131,408,893,1005],"inferior":[132,164],"(95.0%":[143],"84.4%,":[145],"82.8%,":[146],"83.7%).":[147],"It":[148,787,811,829,891],"appears":[149],"from":[150,790,808,919,990,1017],"analysis":[152,227],"that":[153,794,814,934,949],"using":[154,717],"durations":[157],"less":[158],"than":[159,285,731],"17-18":[160],"results":[162,746,902],"outcomes.":[166],"Although":[167],"use":[169,498],"(neo)adjuvant":[174],"setting":[175],"improves":[180],"both":[181,301,713],"OS":[182,223,248,308,453,630,655],"DFS,":[184],"several":[185],"different":[186,474],"clinical":[187,245],"trials":[188,246,613,638,752],"have":[189,331,341,1008],"been":[190],"conducted":[191],"an":[193,334,602],"effort":[194],"to":[195,221,355,385,800,822,964,974,1034,1059,1064],"investigate":[196],"optimal":[198],"duration":[199,337,617,642],"treatment.":[202],"Initially,":[203],"12":[204,358,366,415,481,504,667,950],"months":[205,359,367,416,482,505,668,951,1028],"chosen":[209],"rather":[210],"arbitrarily.":[211],"In":[212,279,347,525,547,722],"setting,":[215,706],"chemotherapy":[216,511,513,687,756,864],"demonstrated":[220],"improve":[222,888],"combined":[226],"North":[230],"Central":[231],"Cancer":[232],"Treatment":[233],"Group":[234,407],"N9831":[235],"National":[238],"Adjuvant":[239],"Breast":[240],"Bowel":[242],"Project":[243],"B-31":[244],"(3).":[247],"improved":[249],"by":[250,255,905],"40%,":[251],"DFS":[253,293,429,529,559,626,651],"improving":[254],"37%":[256],"at":[257,606,980,1038],"a":[258,858,882,922,1009,1018,1045],"median":[259],"follow-up":[260],"8.4":[262],"years.":[263],"Based":[264,593],"these":[266,595,901,986],"studies,":[267,926],"1":[268,324],"month":[269],"became":[274],"standard":[276,677,740,956],"care.":[278,958],"HERA":[281],"study":[282,350,785,793],"more":[284,389,460,692,694,1071],"5000":[286],"women,":[287],"there":[288],"improvement":[291],"2":[295,473,732],"years":[296],"(69%":[299],"1-":[303],"2-year":[305],"arms)":[306],"or":[307,492,774,848,911,921,994],"(79%":[309],"80%)":[311],"(4).":[312],"incidence":[314],"toxicity":[317,456],"year":[325],"More":[328],"recent":[329,461],"studies":[330,462,665],"evaluated":[332,496],"whether":[333],"even":[335],"shorter":[336,1052],"can":[340],"same":[343,517],"(Table":[345],"1).":[346],"PHARE":[349],"3380":[352],"randomized":[354,468],"6":[356,364,413],"noninferiority":[362],"based":[368,743],"prespecified":[370,544],"criteria":[371,545],"could":[372,521],"be":[374,523,601,673,962,1022,1032,1057],"claimed":[375],"(hazard":[376,441],"ratio":[377,442],"=":[378,383,443,446,574,627,631,635,652,656,660],"1.08,":[379],"95%":[380],"confidence":[381],"interval":[382],"0.93":[384],"1.25).":[386],"There":[387,448],"were":[388,578],"12-month":[393,438,540,571,582],"group,":[394],"however":[395],"(5.7%":[396],"1.9%,":[398],"P":[399,445,589],"<":[400,590],".0001)":[401,591],"(5).":[402],"Hellenic":[404],"Oncology":[405],"Research":[406],"481":[420],"patients":[421,695,727,936],"cancer.":[426],"3-year":[428],"95.7%":[431],"93.3%":[433],"favor":[435],"group":[440],"1.57,":[444],".137).":[447],"difference":[451],"(6).":[457],"Three":[458],"other":[459],"demonstrate":[463],"conflicting":[464],"results.":[465],"SHORT-HER":[466],"(Multicentric":[467],"phase":[469],"3":[470,479],"trial":[471,550,772],"chemo":[476],"regimens":[477,514],"plus":[478,688,719,766,818,846],"HER2+":[486],"patients)":[489],"Synergism":[491],"Long":[493],"Duration":[494],"(SOLD)":[495],"9":[500],"weeks":[501],"combination":[509],"(differing":[512],"SHORT-HER,":[516,526],"SOLD).":[519],"Noninferiority":[520],"achieved.":[524],"85%":[531],"9-week":[534],"arm":[535,565,572,583],"88%":[537],"arm,":[541],"achieving":[543],"(7,8).":[546],"PERESPHONE":[549],"2045":[552],"patients,":[557,966],"4-year":[558],"89.4%":[561],"6-month":[564],"89.8%":[568],"(P":[573],".011).":[575],"Cardiac":[576],"higher":[579],"(3%":[586],"8%,":[588],"(9).":[592],"results,":[596],"shortened":[597,1010],"courses":[599,1053],"may":[600,761,868,914,988,1031,1056],"option":[603],"high":[607,1039],"risk":[608,982,1015,1040,1048],"dysfunction.":[611],"Prospective":[612,637],"evaluating":[614,639],"associated":[619,644],"outcomes*":[622,647],"CV=":[623,648],"cardiovascular":[624,649],"events;":[625,650],"survival;":[629,633,654,658],"overall":[632,657,935],"T":[634,659],"With":[662],"current":[664],"available,":[666],"should":[672,961,1006,1021],"continued":[674],"care":[679,742],"receiving":[686],"alone.":[690],"Currently,":[691],"are":[700,1070],"being":[701],"neoadjuvant":[705,755,809,844,863,975],"dual":[709,734,991],"HER2-blocking":[710],"agents":[711],"(blocking":[712],"HER2":[714,735,897,970,992],"HER3)":[716],"pertuzumab":[720,767,847],"though.":[721],"United":[724],"States,":[725],"tumors":[729,910],"greater":[730],"cm,":[733],"blockade":[736,993],"has":[737],"become":[738],"NEOSPHERE":[749],"TRYPHAENA":[751],"(10,11).":[753],"Following":[754],"tumors,":[759],"individuals":[760,841,987,1004],"alone,":[764],"APHINITY":[771],"(12),":[773],"emtansine":[777,797,998],"14":[779],"per":[782],"KATHERINE":[784,792],"(13).":[786],"is":[788,798,812,820,830,892,979],"clear":[789,895,948],"superior":[799,821],"alone":[802,824],"residual":[806],"disease":[807],"chemotherapy.":[810],"suggestive":[813],"doublet":[815],"therapy":[816,880],"(trastuzumab":[817],"pertuzumab)":[819],"setting.":[828,1002],"unclear,":[831],"however,":[832],"how":[833,849,896],"affects":[838,854],"received":[843],"achieved":[857],"complete":[859,883],"pathologic":[860,884],"response":[861,885,973],"after":[862],"which":[866],"do":[869,937],"extremely":[870,938],"well":[871,939],"regardless.":[872],"For":[873],"example,":[874],"triple-negative":[876],"cancer,":[878],"additional":[879],"following":[881],"does":[886],"(14).":[890],"heterogeneity":[898],"plays":[899],"into":[900],"(15).":[903],"Stratifying":[904],"molecular":[906],"subtypes":[907],"estrogen":[912],"status":[913],"help":[915],"outline":[916],"benefits":[918],"drug":[923],"conjugate.":[924],"Other":[925],"particularly":[927,1061],"low-risk":[929],"cancers,":[932],"suggest":[933],"little":[941],"HER2-based":[942],"therapies":[943],"(16).":[944],"Today,":[945],"it":[946],"seems":[947],"remains":[954],"Further":[959],"efforts":[960],"made":[963],"risk-stratify":[965],"genomic":[968],"profile,":[969],"heterogeneity,":[971],"chemotherapy,":[976],"determining":[977],"highest":[981],"recurrence,":[984],"because":[985],"benefit":[989],"consideration":[995],"These":[1003],"course":[1011],"Similar":[1014],"stratification":[1016],"perspective":[1020],"performed":[1023],"all":[1025],"patients.":[1026],"Six":[1027],"reasonable":[1033,1058],"consider":[1035],"dysfunction":[1043],"low":[1046],"biologic":[1047],"recurrence.":[1050],"Finally,":[1051],"consider,":[1060],"low-":[1063],"middle-income":[1065],"countries":[1066],"where":[1067],"resources":[1069],"limited.":[1072],"Disclosures:":[1073],"No":[1074],"disclosures.":[1075],"Acknowledgment:":[1076],"We":[1077],"thank":[1078],"Dr":[1079],"Douglas":[1080],"Yee":[1081],"reviewing":[1083],"manuscript.":[1085]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2025-10-10T00:00:00"}